Strategic Partnerships Cooperate with Coegin Pharma and Lund University to leverage X-ray crystallography for tissue-repair peptide drug candidates, offering integrated MX services and fragment screening to accelerate early-stage programs.

Fragment Screening Market SARomics WAC and crystallographic fragment screening capabilities as a fast, low-cost entry point for identifying hit compounds, appealing to biotech startups and CROs seeking rapid lead generation.

Biosimilar Support Position services in higher order structure verification and antigen-antibody complex crystallography as critical for biosimilar comparability studies, targeting biopharma companies expanding biosimilar portfolios.

Integrated Drug Discovery Highlight end-to-end offerings from protein structure determination to computational screening and fragment libraries, enabling customers to consolidate multiple workflows under one partner and reduce vendor management.

Proximity Advantage Leverage Medicon Village proximity to MAX IV Laboratory to emphasize access to top-tier synchrotron facilities for rapid data generation, appealing to research groups needing high-throughput structural data.